GU Cancers 2023 | TRITON3 interim OS results demonstrate superiority of rucaparib over docetaxel for mCRPC

Alan Haruo Bryce, MD, Mayo Clinic, Rochester, MN, reports on the interim overall-survival (OS) results of the Phase III TRITON3 (NCT02975934) trial assessing rucaparib versus physician’s choice in patients with chemotherapy-naïve metastatic castration resistant prostate cancer (mCRPC) with BRCA1/2 (BRCA) or ATM alterations. The primary endpoint was radiographic progression-free survival (rPFS) first tested in the BRCA subgroup, then the intent-to-treat (ITT) population and OS was a key secondary endpoint. 302 pts with BRCA and 103 pts with ATM alterations were randomized. OS maturity was 54% in the BRCA subgroup and 59% in the ITT population. The results were positive, demonstrating the superiority of rucaparib over physician’s choice. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.